Announcement No.: 2026-25
Qianjiang Yong'an Pharmaceutical Co., Ltd. Announcement on Changes to Business Scope and Amendments to the Articles of Association
The Company and the entire Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and that there are no false records, misleading statements, or material omissions.
Qianjiang Yong'an Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") held the 15th meeting of the 7th Board of Directors on April 29, 2026, and approved the "Proposal on Changes to the Business Scope and Amendments to the Articles of Association." This proposal needs to be submitted to the Company's shareholders' meeting for deliberation. The relevant situation is announced as follows:
I. Changes to the Company's Business Scope
To optimize the management structure, improve operational efficiency, reduce management costs, and integrate high-quality resources, the Company held the 12th extraordinary meeting of the 7th Board of Directors on January 6, 2026, and the first extraordinary shareholders' meeting of 2026 on January 22, 2026. Both meetings approved the "Proposal on the Absorption and Merger of Wholly-owned Subsidiary Hubei Ling'an Technology Co., Ltd." and agreed to the overall absorption and merger of its wholly-owned subsidiary Hubei Ling'an Technology Co., Ltd. (hereinafter referred to as "Ling'an Technology"). Upon completion of this absorption and merger, Ling'an Technology's legal entity status will be legally cancelled, and all its assets, claims, debts, businesses, personnel, and other rights and obligations will be inherited by the Company. In January 2026, the Company signed the "Absorption and Merger Agreement" with Ling'an Technology and published a notice to creditors. For detailed information, please refer to the relevant announcements published by the Company on the designated information disclosure media of the China Securities Regulatory Commission, Cninfo.com.cn.
Given that Ling'an Technology's related businesses will be merged into the Company, and considering the Company's actual operating and business development needs, the Company proposes to change its business scope. The final business scope will be subject to the approval and registration results of the Administration for Market Regulation. The specific changes are as follows: